EPO and anemia (phenotype): Pharmacological activation of IRP1 could be a therapeutic strategy to treat Chuvash polycythemia and pulmonary hypertension, and inhibition of the interaction between IRP1 and HIF2α could increase EPO production and potentially treat anemia, and thus modulations of IRP1 activity should be investigated further.